a full submission assessed under the end of life medicine process:
pembrolizumab (Keytruda®) is accepted for restricted use within NHSScotland.
Indication under review: In combination with carboplatin and either paclitaxel or nabpaclitaxel,
for the first-line treatment of metastatic squamous non-small cell lung cancer
(NSCLC) in adults.
SMC restriction: in combination with carboplatin and paclitaxel in patients whose tumours
express programmed death ligand 1 (PD-L1) with a <50% tumour proportion score (TPS), or
in those whom it has not been possible to evaluate PD-L1 TPS. Treatment with
pembrolizumab is subject to a two-year clinical stopping rule.
Pembrolizumab in combination with platinum based doublet chemotherapy was associated
with a progression-free survival and overall survival benefit over platinum based doublet
chemotherapy in patients with treatment naïve metastatic squamous NSCLC.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that
improves the cost-effectiveness of pembrolizumab. This advice is contingent upon the
continuing availability of the PAS in NHSScotland or a list price that is equivalent or lower.
This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.
- Medicine name:
- pembrolizumab (Keytruda)
- SMC ID:
In combination with carboplatin and either paclitaxel or nab-paclitaxel, is indicated for the first-line treatment of metastatic squamous NSCLC in adult.
- Pharmaceutical company
- Merck Sharp & Dohme Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published
- 09 September 2019